Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Therapy vs Standard Therapy in Elderly AML and MDS
NCT05025098Phase 2Recruiting
- Start
- Jun 2021
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms). Primary endpoint: Cost-effectiveness of a precision therapy strategy. Started Jun 2021; status: recruiting.
02
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05025098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05025098.